On December 11, according to Reuters, Eli Lilly and Co's CEO David Ricks stated on Tuesday that tax and regulatory reforms as well as drug affordability are the company's policy priorities under the Trump administration. Trump met with Ricks and the Industry lobbying group PhRMA's CEO in Florida last week, and Pfizer's CEO Albert Bourla was also involved in the meeting. Ricks did not disclose details of the discussions and did not provide more information on the specific reforms he is targeting. He indicated that the regulatory environment in the USA has negatively affected the pharmaceutical industry over the past four years. The Trump administration may propose a policy argument that other developed countries should pay more for medications, which could lower drug prices in the USA. Americans pay more for medications than any other country. Pharmaceutical executives had previously stated that once Trump returns to the White House, they would advocate for revising new laws that allow Insurance to negotiate prices for its most expensive prescription drugs and reform the rules governing the negotiation of bulk discounts with Drug Manufacturers by pharmacy middlemen.